N/A
N=19
PET Imaging and Olanzapine Treatment in Borderline Personality Disorder
Borderline Personality Disorder
Bottom Line
View on ClinicalTrials.gov: NCT00275301 ↗Enrolled (actual)
19
Serious AEs
0.0%
Results posted
May 2017
Primary outcome: Primary: Change in Brain Metabolism From Baseline to Eight Weeks as Seen in PET Scan — 11.5 Standard uptake value — p=<0.05
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- olanzapine (Drug)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- University of Minnesota
- Primary completion
- Apr 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Brain Metabolism From Baseline to Eight Weeks as Seen in PET Scan |
11.5 | <0.05 sig |
Summary
The overall design of the study is to perform both a PET and MRI scan on objectively identified borderline personality disorder patients, to treat them with olanzapine for 8 weeks, and to then re-scan the patients with PET.
Eligibility Criteria
Inclusion Criteria
- Age 18-45 years
- Diagnosis: borderline personality disorder by DSM-IV criteria
- Gender: Female
- May have history of substance use and other Axis II disorders
Exclusion Criteria
- Axis I diagnosis of schizophrenia, schizoaffective disorder, or bipolar I disorder during the subject's lifetime. No current major depression or PTSD.
- Treatment with psychotropic medication in the previous month.
- Medical disorder that would influence outcome of the study - e.g. epilepsy, thyroid disease, HIV, etc.
- Medical disorder that would not allow use of olanzapine
- Active substance abuse or dependence
- Previous adverse reaction to olanzapine
- Females whom are pregnant or nursing
Data sourced from ClinicalTrials.gov (NCT00275301). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.